Latest Developments in Alzheimer’s Drugs

Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug. There is 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. Development pipeline as represented on clinical trials.

 

  • BACE Inhibitors
  • Passive Immunotherapy
  • Enhancing Cognition
  • Anti-Amyloid Treatment
  • Targets for future drugs

Related Conference of Latest Developments in Alzheimer’s Drugs

Latest Developments in Alzheimer’s Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in